AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2024
Dec 5, 2024
32159_dirs_2024-12-04_b1b6ff74-c6e8-40a8-9b24-e4893f5e5bb9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-12-02
Reporting Person: Shawver Laura (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-02 | Common Stock | M | 67616 | $1.27 | Acquired | 277962 | Direct |
| 2024-12-02 | Common Stock | M | 29628 | $1.27 | Acquired | 307590 | Direct |
| 2024-12-02 | Common Stock | S | 96343 | $13.5539 | Disposed | 211247 | Direct |
| 2024-12-02 | Common Stock | S | 901 | $14.3417 | Disposed | 210346 | Direct |
| 2024-12-03 | Common Stock | M | 25606 | $1.27 | Acquired | 235952 | Direct |
| 2024-12-03 | Common Stock | M | 62378 | $3.15 | Acquired | 298330 | Direct |
| 2024-12-03 | Common Stock | S | 87984 | $13.2626 | Disposed | 210346 | Direct |
| 2024-12-04 | Common Stock | M | 14772 | $3.15 | Acquired | 225118 | Direct |
| 2024-12-04 | Common Stock | S | 14772 | $13.7496 | Disposed | 210346 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-02 | Stock Option (Right to Buy) | $1.27 | M | 29628 | Disposed | 2030-04-28 | Common Stock (29628) | Direct |
| 2024-12-02 | Stock Option (Right to Buy) | $1.27 | M | 67616 | Disposed | 2030-04-28 | Common Stock (67616) | Direct |
| 2024-12-03 | Stock Option (Right to Buy) | $1.27 | M | 25606 | Disposed | 2030-04-28 | Common Stock (25606) | Direct |
| 2024-12-03 | Stock Option (Right to Buy) | $3.15 | M | 62378 | Disposed | 2032-05-01 | Common Stock (62378) | Direct |
| 2024-12-04 | Stock Option (Right to Buy) | $3.15 | M | 14772 | Disposed | 2032-05-01 | Common Stock (14772) | Direct |
Footnotes
F1: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
F2: The weighted average sale price for the transaction reported was $13.5539 and the range of prices were between $13.27 and $14.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $14.3417 and the range of prices were between $14.2761 and $14.375. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: The weighted average sale price for the transaction reported was $13.2626 and the range of prices were between $12.92 and $13.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: The weighted average sale price for the transaction reported was $13.7496 and the range of prices were between $13.39 and $14.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6: Immediately exercisable.
F7: Due to a clerical error, the total number of shares subject to this option grant was underreported by one share on the Reporting Person's Form 3 and is corrected on this filing.